TSRO Key Stats
- Are These Top Post-IPO Performers Still a Buy? Fool May 21
- Nasdaq stocks posting largest percentage increases May 20
- Cramer's 'Mad Money' Recap: Think Dividends, Not Coupons May 20
- The Best- And Worst- Performing Biotech Stocks, May 10 To May 17 May 19
- 3 Humongous Health-Care Stocks This Week Fool May 18
- 4 Healthcare Stock Stories For Thursday Investing Wellness May 16
- Nasdaq stocks posting largest percentage increases May 16
- Why Tesaro Shares Vaulted Higher Fool May 16
- TESARO rises after data support advancement of drug to Phase 3 trials May 16
- Tesaro Final Phase 1 Results Demonstrate Activity in Ovarian and Breast Cancer, ... May 16
TSRO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Tesaro is up 0.99% over the last year vs S&P 500 Total Return up 31.95%, Halozyme Therapeutics down 3.99%, and Oramed Pharmaceuticals down 96.83%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for TSRO
Pro Report PDF for TSRO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download TSRO Pro Report PDF
Pro Strategies Featuring TSRO
Did Tesaro make it into our Pro Portfolio Strategies?